More people are surviving cancer thanks to research gained through cancer clinical trials. With the collective help of doctors, researchers and cancer patients who choose to participate, cancer clinical trials are able to test the value of the latest research findings of the National Cancer Institute (NCI).

Rex Cancer Center participates in ongoing cancer clinical trials in collaboration with the University of North Carolina-Chapel Hill. These trials can take several years to complete. They are required by law to include a protocol or action plan for each patient as well as informed consent. In return, knowledge gained from these trials has led to increased survival for many cancers including Hodgkin's disease, certain leukemias, breast, uterine, testicular and bladder cancers.

Cancer knows no boundaries. It touches everyone, whether through personal diagnosis or knowledge of someone with cancer. The statistics are alarming, but the good news is that dramatic improvements have been made in the diagnosis and treatment of cancer as a direct result of invaluable research of cancer clinical trials. The trials open currently at Rex Cancer Center include the following:

Breast Cancer

NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy - (also open at the Rex Cancer Center of Wakefield)

NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (six cycles of Docetaxel plus Cyclophosphamide or four cycles of Doxorubicin plus Cyclophosphamide followed by weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-positive or High-risk Node-negative HER2 Low Invasive Breast Cancer - (also open at the Rex Cancer Center of Wakefield)

NSABP B-49: A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer- (also open at the Rex Cancer Center of Wakefield)

Esophageal

RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2+ Esophageal Adenocarcinoma

Gastrointestinal Cancers

LCCC 1029: Randomized Placebo-Controlled Phase II Study of Regorafenib in Combination with FOLFIRI versus Placebo & FOLFIRI as 2nd Line Treatment in Patients with K-RAS or BRAF Mutant Metastatic Colorectal Cancer

Lymphoma

LCCC 1011:  A Phase II Trial of Bendamustine in Combination with Rituximab in Older Patients w Previously Untreated Diffuse Large B-cell Lymphoma

S1001: A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma. 

Hodgkin Lymphoma

LCCC 1115:  A Pilot Feasibility Trial of Induction Chemotherapy with ABVD Followed by Brentuximab Vedotin (SGN-35) Consolidation in Patients with Previously Untreated Non-Bulky Stage I or II Hodgkin Lymphoma (HL)

Chronic Phase CML (Chronic Myeloid Leukemia)

CAMN107AUS12T:  Pilot Study to Assess Telemonitoring of Gleevec® (imatinib mesylate) or Tasigna® (nilotinib) Therapy - (also open at the Rex Cancer Center of Wakefield)

Myelodysplastic Syndrome

ECOG 2905:  Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response to Treatment with Lenalidomide Alone and in Combination with Epoetin Alfa in Subjects with Low or Intermediate-1 Risk MDS and Asymptomatic Anemia

Pancreatic Cancers

RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

AGICC 11PAN01 ---- A Phase II/III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined with Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer

Prostate Cancer

RTOG 0534: A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy

RTOG 0815: A Phase III Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer

RTOG 0924: A Phase III Randomized Trial of Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer

Miscellaneous Studies

LCCC 0916: Carolina Senior: UNC Registry for Older Patients - (also open at the Rex Cancer Center of Wakefield)

FDG Dynamic Scan Study: Pilot Study for Monitoring Changes in 18F-fluorodeoxyglucose (FDG) with a surface applicator to predict effect of therapy

Registry Study

LCCC 0916: Carolina Senior: UNC Registry for Older Patients - (also open at the Rex Cancer Center of Wakefield)

Lung Cancer

ECOG 1505: A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for patients with completely resected Stage IB (≥ 4 cm) - IIIA Non-Small Cell Lung Cancer

LCCC 0921: A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab

RTOG 1012: A Phase II Randomized Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy Induced Esophagitis-Related Pain During the Treatment of Lung Cancer

Helpful Websites

UNC Lineberger Comprehensive Cancer Center

US National Institutes of Health

Cancer clinical trials available today are early detection/screening trials, diagnostic trials, quality-of-life/supportive care trials, treatment trials and prevention trials.

For more information about clinical trials open at Rex Cancer Center, call our oncology research manager, Nancy Burns, at (919) 784-7209.